SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

Trading Statement

9 Oct 2014 07:00

RNS Number : 8130T
Victrex PLC
09 October 2014
 



 

 

 

 

9 October 2014

 

Victrex plc - Pre-close trading statement

 

"A strong finish to 2014 - growth momentum continues"

 

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its pre-close trading statement for the financial year ended 30 September 2014, ahead of its preliminary results on Tuesday 9 December 2014.

 

Victrex delivered a strong finish to 2014, with the Group continuing its volume growth momentum from the first half year across our strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Full year Group sales volume of 3,551 tonnes increased by 22% (2013: 2,920 tonnes), with second half year sales volume of 1,967 tonnes increasing by 29% on last year (H2 2013: 1,528 tonnes). Although sales volumes were particularly strong, our profit expectations remain largely unchanged.

 

The strong volume performance in our Victrex Polymer Solutions (VPS) business reflects core growth and higher than expected volumes in the second half year from Consumer Electronics. Stripping out sales volumes across the entire Electronics segment, second half year sales volume increased by 6% on the prior year. Our higher margin Speciality Products business, including Aptiv film, again performed well during the year. With continued growth in Aptiv, we will bring an additional production line on stream during the first half of our new financial year.

 

In our higher margin Invibio medical business, full year revenue increased by 5% to £53.4m (2013: £50.8m), reflecting steady improvement in the Spine market. The focus for 2015 remains the roll-out of new products into the Spine market, with regulatory applications lodged in the US and Europe for the innovative PEEK-OPTIMA® HA-Enhanced product, which enhances bone-on-growth. Pending regulatory approval, adoption and roll-out will commence during the first half.

 

As we start our new financial year, our growth momentum remains positive. Although currency headwinds remain considerable in 2015, our forthcoming new PEEK and Aptiv film capacity, technical excellence and marketing know-how keep us well placed to continue driving growth and creating value, in line with our long term strategy.

 

Enquiries:

 

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 1253 898121

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead / Rebecca Hall +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions focused on the strategic markets of Aerospace, Automotive, Electronics, Energy and Medical. Every day, millions of people rely on products or applications which contain our polymers, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are investing in technical excellence to deliver new and leading edge solutions to our customers and our markets, and to drive value for our shareholders. Visit www.victrexplc.com

 

Investor and analyst call:

A call for investors and analysts will be held today, Thursday 9 October 08.30 UK time. For dial in details contact Rebecca Hall at Pendomer on +44 (0) 203 603 5220 or Rebecca.Hall@pendomer.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTUGGBAUUPCGCR
Date   Source Headline
29th Apr 20221:16 pmRNSTotal Voting Rights
21st Apr 20222:50 pmRNSHolding(s) in Company
20th Apr 202212:20 pmRNSDirector/PDMR Shareholding
5th Apr 20227:00 amRNSDirectorate Change
31st Mar 202210:39 amRNSTotal Voting Rights
22nd Mar 202211:35 amRNSDirector/PDMR Shareholding
18th Mar 202210:09 amRNSHolding(s) in Company
17th Mar 202212:21 pmRNSDirector/PDMR Shareholding
15th Mar 20223:07 pmRNSAdditional Listing
28th Feb 202210:46 amRNSTotal Voting Rights
22nd Feb 20221:14 pmRNSDirector/PDMR Shareholding
17th Feb 202212:30 pmRNSDirector/PDMR Shareholding
15th Feb 202212:12 pmRNSHolding(s) in Company
11th Feb 202212:21 pmRNSResult of AGM
11th Feb 20227:00 amRNSAGM & Q1 Interim Management Statement
10th Feb 20222:06 pmRNSDirector/PDMR Shareholding
10th Feb 202210:15 amRNSHolding(s) in Company
31st Jan 202210:23 amRNSTotal Voting Rights
28th Jan 20223:23 pmRNSHolding(s) in Company
24th Jan 20223:54 pmRNSHolding(s) in Company
20th Jan 20229:21 amRNSAdditional Listing
18th Jan 20223:11 pmRNSDirector/PDMR Shareholding
6th Jan 20222:14 pmRNSAnnual Report and Accounts
6th Jan 20229:53 amRNSDirector/PDMR Shareholding
31st Dec 20219:00 amRNSTotal Voting Rights
17th Dec 20213:59 pmRNSHolding(s) in Company
17th Dec 202112:01 pmRNSDirector/PDMR Shareholding
16th Dec 20211:06 pmRNSDirector/PDMR Shareholding
13th Dec 202111:20 amRNSDirector/PDMR Shareholding
6th Dec 20217:00 amRNSVictrex plc – Preliminary Results 2021
1st Dec 20213:48 pmRNSBlock listing Interim Review
30th Nov 202111:39 amRNSTotal Voting Rights
18th Nov 20212:12 pmRNSDirector Declaration
17th Nov 202112:17 pmRNSDirector/PDMR Shareholding
9th Nov 20211:51 pmRNSDirector Declaration - Replacement
9th Nov 20219:00 amRNSDirector Declaration
29th Oct 20219:25 amRNSTotal Voting Rights
21st Oct 20217:00 amRNSVictrex signs up to SBTi
19th Oct 202111:13 amRNSDirector/PDMR Shareholding
15th Oct 20217:00 amRNSDirectorate Change
14th Oct 20217:00 amRNSTechnipFMC to acquire Victrex’s Magma equity
30th Sep 20212:22 pmRNSTotal Voting Rights
20th Sep 20217:00 amRNSChair-designate appointment
17th Sep 202110:51 amRNSDirector/PDMR Shareholding
31st Aug 202110:23 amRNSTotal Voting Rights
18th Aug 20214:11 pmRNSDirector/PDMR Shareholding
30th Jul 202112:18 pmRNSTotal Voting Rights
19th Jul 202110:21 amRNSDirector/PDMR Shareholding
9th Jul 20217:00 amRNSVictrex Q3 Interim Management Statement
30th Jun 202110:23 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.